In addition, previous studies have revealed that fewer than 30% of males with PSA levels in the gray zone have pathologically confirmed PCa, and the detection rate for clinically significant prostate cancer (CSPCa) is much lower [3]. The gene discussed is KLK3; the disease is prostate carcinoma.